Skip to main content

ADVERTISEMENT

Lung Cancer

Videos
11/24/2019
Edward B. Garon, MD, MS, discusses current approaches for the first-line treatment of patients with EGFR-positive NSCLC.
Edward B. Garon, MD, MS, discusses current approaches for the first-line treatment of patients with EGFR-positive NSCLC.
Edward B. Garon, MD, MS,...
11/24/2019
Oncology
06/03/2019
Findings presented at ASCO 2019 show that first-line pemetrexed plus carboplatin and gefitinib is a new standard treatment option for patients with EGFR-positive NSCLC.
Findings presented at ASCO 2019 show that first-line pemetrexed plus carboplatin and gefitinib is a new standard treatment option for patients with EGFR-positive NSCLC.
Findings presented at ASCO 2019...
06/03/2019
Oncology
06/01/2019
Interim data from a large study of patients with early-stage NSCLC being presented at ASCO 2019 show that neoadjuvant atezolizumab is well-tolerated, and yields encouraging responses.
Interim data from a large study of patients with early-stage NSCLC being presented at ASCO 2019 show that neoadjuvant atezolizumab is well-tolerated, and yields encouraging responses.
Interim data from a large study...
06/01/2019
Oncology
06/01/2019
Study findings presented at ASCO 2019 show that daily metformin use combined with chemoradiotherapy for locally advanced NSCLC was well-tolerated but did not improve survival.
Study findings presented at ASCO 2019 show that daily metformin use combined with chemoradiotherapy for locally advanced NSCLC was well-tolerated but did not improve survival.
Study findings presented at ASCO...
06/01/2019
Oncology